Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy [Seeking Alpha]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Seeking Alpha
CRSP's commercial launch of Casgevy is progressing, with their share of a $100M+ 2025 total revenue expectation, and significant growth expected into 2026. The pipeline's cardiovascular assets (CTX310/320) show promising early efficacy, with huge addressable markets and the potential to disrupt standard-of-care regimens. CRSP's strong balance sheet, new Sirius Therapeutics collaboration, and institutional support provide ample runway and strategic flexibility for long-term value creation. quantic69/iStock via Getty Images Crispr Therapeutics AG ( CRSP ) was founded in 2013 and is based in Zug, Switzerland. It is the market leader in transformative therapies incorporating CRISPR/Cas9 technology, solidifying its position after receiving approval by the FDA (Dec 2023) & EMA (Feb 2024) for Casgevy This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of CRSP, VRTX either through stock ownership, options, or other derivatives. I w
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- CRISPR Therapeutics: CTX310 De-Risks, CASGEVY Disappoints Amid Takeover Rumors [Seeking Alpha]Seeking Alpha
- What CRISPR Therapeutics' (CRSP) Latest Trial Results Mean for Investors [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics (CRSP): Assessing Valuation in Light of Recent Share Price Volatility [Yahoo! Finance]Yahoo! Finance
- Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics (NASDAQ:CRSP) was given a new $74.00 price target on by analysts at Chardan Capital.MarketBeat
CRSP
Earnings
- 11/10/25 - Beat
CRSP
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/10/25 - Form 10-Q
- 11/10/25 - Form 8-K
- CRSP's page on the SEC website